Go Pro
Mark Massaro

Mark Massaro Analyst Performance

Managing Director, Senior Equity Research Analyst at BTIG Research

Mark Massaro is a stock analyst at BTIG Research in the healthcare sector, covering 31 publicly traded companies. Over the past year, Mark Massaro has issued 92 stock ratings, including buy, hold, and sell recommendations. While full access to Mark Massaro's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Mark Massaro's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
271 Last 11 Years
Buy Recommendations
90.19% 239 Buy Ratings
Companies Covered
31 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy90.2%239 ratings
Hold9.1%24 ratings
Sell0.8%2 ratings

Out of 265 total stock ratings issued by Mark Massaro at BTIG Research, the majority (90.2%) have been Buy recommendations, followed by 9.1% Hold and 0.8% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
77.4% of companies on NASDAQ
24 companies
NYSE
16.1% of companies on NYSE
5 companies
OTCMKTS
6.5% of companies on OTCMKTS
2 companies

Mark Massaro, an analyst at BTIG Research, currently covers 31 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
31 companies
100.0%

Mark Massaro of BTIG Research specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
HEALTHCARE PROVIDERS & SERVICES
8 companies
25.8%
HEALTHCARE EQUIPMENT & SUPPLIES
8 companies
25.8%
LIFE SCIENCES TOOLS & SERVICES
6 companies
19.4%
BIOTECHNOLOGY
5 companies
16.1%
HEALTHCARE TECHNOLOGY
2 companies
6.5%
PHARMACEUTICALS
1 company
3.2%
DIAGNOSTIC SUBSTANCES
1 company
3.2%

About Mark Massaro

Mark Massaro is a Managing Director and BTIG Life Science and Diagnostic Tools Analyst. Prior to BTIG, he served as the Chief Financial Officer at ArcherDX, Inc., an oncology diagnostics and pharmaceutical services company, which was acquired by Invitae Corporation. Previously, Mr. Massaro was a Managing Director and Senior Equity Research Analyst within Diagnostics and Life Science Tools at Canaccord Genuity, where he spent more than eight years focused on high-growth, precision medicine and next-generation sequencing companies, as well as molecular and point-of-care diagnostics, reference labs and animal health. He was named a “Rising Star” in Institutional Investor’s All America Survey for life science and diagnostics tools in October 2016. Earlier in his career, Mr. Massaro was an Associate Equity Analyst within Healthcare Services at Avondale Partners and held corporate finance and financial reporting roles at Dell EMC and Fidelity Investments. He earned an MBA from Babson College and a BA in economics and Spanish from the University of Massachusetts – Amherst.
Follow on LinkedIn

Mark Massaro's Ratings History at BTIG Research

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
GeneDx Holdings Corp. stock logo
WGS
GeneDx
8/4/2026Reiterated Rating$67.86$90.00Buy
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
8/3/2026Boost Price Target$28.00$44.00Buy
Tempus AI, Inc. stock logo
TEM
Tempus AI
8/3/2026Lower Price Target$46.74$70.00Buy
Guardant Health, Inc. stock logo
GH
Guardant Health
7/31/2026Boost Price Target$152.35$195.00Buy
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
7/30/2026Boost Price Target$22.56$25.00Buy
Personalis, Inc. stock logo
PSNL
Personalis
7/20/2026Boost Price Target$13.68$16.25Buy
CareDx, Inc. stock logo
CDNA
CareDx
7/16/2026Boost Price Target$37.31$45.00Buy
Caris Life Sciences, Inc. stock logo
CAI
Caris Life Sciences
7/2/2026Reiterated Rating$18.75$32.00Buy
Guardant Health, Inc. stock logo
GH
Guardant Health
7/1/2026Boost Price Target$165.84$190.00Buy
Natera, Inc. stock logo
NTRA
Natera
6/24/2026Set Price Target$260.53$275.00Buy
Natera, Inc. stock logo
NTRA
Natera
6/23/2026Boost Price Target$235.22$270.00Buy
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
6/17/2026Reiterated Rating$16.79$22.00Buy
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
6/15/2026Reiterated Rating$4.88$8.00Buy
Tempus AI, Inc. stock logo
TEM
Tempus AI
6/1/2026Reiterated Rating$50.47$80.00Buy
Guardant Health, Inc. stock logo
GH
Guardant Health
5/27/2026Set Price Target$125.59$160.00Buy
Guardant Health, Inc. stock logo
GH
Guardant Health
5/26/2026Boost Price Target$118.95$155.00Buy
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
5/15/2026Reiterated Rating$1.02$2.50Buy
MDxHealth SA stock logo
MDXH
MDxHealth
5/14/2026Lower Price Target$1.95$4.00Buy
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
5/13/2026Lower Price Target$18.63$40.00Buy
Exagen Inc. stock logo
XGN
Exagen
5/12/2026Lower Price Target$3.98$8.00Buy
Personalis, Inc. stock logo
PSNL
Personalis
5/11/2026Lower Price Target$5.98$11.00Buy
Natera, Inc. stock logo
NTRA
Natera
5/11/2026Lower Price Target$200.24$250.00Buy
Caris Life Sciences, Inc. stock logo
CAI
Caris Life Sciences
5/8/2026Lower Price Target$19.84$32.00Buy
Tempus AI, Inc. stock logo
TEM
Tempus AI
5/8/2026Lower Price Target$49.02$80.00Buy
Billiontoone, Inc. stock logo
BLLN
Billiontoone
5/7/2026Lower Price Target$81.40$130.00Buy
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
5/6/2026Reiterated Rating$13.78$22.00Buy
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
5/6/2026Reiterated Rating$5.07$8.00Buy
GeneDx Holdings Corp. stock logo
WGS
GeneDx
5/5/2026Lower Price Target$67.93$90.00Buy
Cerus Corporation stock logo
CERS
Cerus
5/1/2026Upgrade$2.03$4.00Buy
CareDx, Inc. stock logo
CDNA
CareDx
4/29/2026Boost Price Target$21.91$28.00Buy
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
4/15/2026Boost Price Target$4.96$8.00Buy
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
3/30/2026Reiterated Rating$1.12$2.50Buy
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
3/24/2026Reiterated Rating$104.91Neutral
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
3/12/2026Lower Price Target$6.84$5.00Sell
Exagen Inc. stock logo
XGN
Exagen
3/10/2026Lower Price Target$3.33$9.00Buy
Billiontoone, Inc. stock logo
BLLN
Billiontoone
3/5/2026Lower Price Target$80.83$140.00Buy
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
3/3/2026Reiterated Rating$4.04$7.00Buy
Caris Life Sciences, Inc. stock logo
CAI
Caris Life Sciences
2/27/2026Lower Price Target$19.24$38.00Buy
Zoetis Inc. stock logo
ZTS
Zoetis
2/26/2026Reiterated Rating$129.15$160.00Buy
CareDx, Inc. stock logo
CDNA
CareDx
2/25/2026Boost Price Target$18.46$26.00Buy
He bet half his $9 billion on ONE stock (Ad)

One of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund - into a single, little-known company. His firm then bought more shares for 61 straight trading days, and the former CEO of Google soon struck a nine-figure partnership with the same company. This company controls nearly a million acres of scarce, irreplaceable minerals now protected by a White House executive order signed January 14, 2026. It has already outperformed Apple, Amazon, and the S-P 500 combined - and Whitney Tilson believes the biggest gains are still ahead.tc pixel

Watch the free presentation and get the name and ticker now
Tempus AI, Inc. stock logo
TEM
Tempus AI
2/25/2026Lower Price Target$57.95$90.00Buy
GeneDx Holdings Corp. stock logo
WGS
GeneDx
2/24/2026Lower Price Target$87.08$170.00Buy
Guardant Health, Inc. stock logo
GH
Guardant Health
2/20/2026Boost Price Target$106.38$145.00Buy
Exagen Inc. stock logo
XGN
Exagen
2/17/2026Lower Price Target$3.28$10.00Buy
Personalis, Inc. stock logo
PSNL
Personalis
2/11/2026Boost Price Target$8.90$13.00Buy
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2/6/2026Boost Price Target$16.47$22.00Buy
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2/3/2026Lower Price Target$639.60$800.00Buy
Personalis, Inc. stock logo
PSNL
Personalis
1/9/2026Reiterated Rating$8.38$12.00Buy
MDxHealth SA stock logo
MDXH
MDxHealth
12/23/2025Reiterated Rating$3.40$7.00Buy
Guardant Health, Inc. stock logo
GH
Guardant Health
12/12/2025Boost Price Target$101.38$140.00Buy
GeneDx Holdings Corp. stock logo
WGS
GeneDx
12/12/2025Boost Price Target$155.37$200.00Buy
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
12/12/2025Boost Price Target$37.97$50.00Buy
Billiontoone, Inc. stock logo
BLLN
Billiontoone
12/10/2025Reiterated Rating$109.53$160.00Buy
Natera, Inc. stock logo
NTRA
Natera
12/5/2025Boost Price Target$244.55$260.00Buy
Zoetis Inc. stock logo
ZTS
Zoetis
12/3/2025Reiterated Rating$124.44$160.00Buy
Billiontoone, Inc. stock logo
BLLN
Billiontoone
12/1/2025Initiated Coverage$130.18$160.00Buy
Billiontoone, Inc. stock logo
BLLN
Billiontoone
12/1/2025Initiated Coverage$113.04$160.00Buy
Tempus AI, Inc. stock logo
TEM
Tempus AI
11/25/2025Boost Price Target$76.06$105.00Buy
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
11/20/2025Downgrade$100.99Neutral
MDxHealth SA stock logo
MDXH
MDxHealth
11/13/2025Boost Price Target$4.12$7.00Buy
Zoetis Inc. stock logo
ZTS
Zoetis
11/12/2025Lower Price Target$120.09$160.00Buy
Personalis, Inc. stock logo
PSNL
Personalis
11/11/2025Boost Price Target$8.63$12.00Buy
Exagen Inc. stock logo
XGN
Exagen
11/10/2025Boost Price Target$9.56$15.00Buy
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
11/10/2025Boost Price Target$4.37$7.00Buy
Natera, Inc. stock logo
NTRA
Natera
11/7/2025Boost Price Target$198.48$230.00Buy
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
11/6/2025Boost Price Target$15.56$21.00Buy
CareDx, Inc. stock logo
CDNA
CareDx
11/6/2025Boost Price Target$16.53$25.00Buy
Tempus AI, Inc. stock logo
TEM
Tempus AI
11/5/2025Reiterated Rating$84.49$96.00Buy
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
11/4/2025Boost Price Target$31.63$38.00Buy
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
11/4/2025Boost Price Target$722.94$830.00Buy
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
11/4/2025Boost Price Target$66.98$85.00Buy
Guardant Health, Inc. stock logo
GH
Guardant Health
10/30/2025Boost Price Target$72.27$100.00Buy
GeneDx Holdings Corp. stock logo
WGS
GeneDx
10/29/2025Boost Price Target$137.47$165.00Buy
Natera, Inc. stock logo
NTRA
Natera
10/23/2025Boost Price Target$192.51$210.00Buy
Tempus AI, Inc. stock logo
TEM
Tempus AI
10/22/2025Boost Price Target$89.10$96.00Buy
Personalis, Inc. stock logo
PSNL
Personalis
10/22/2025Boost Price Target$9.57$11.00Buy
GeneDx Holdings Corp. stock logo
WGS
GeneDx
10/22/2025Boost Price Target$121.77$140.00Buy
Exagen Inc. stock logo
XGN
Exagen
10/22/2025Boost Price Target$11.69$13.00Buy
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
10/22/2025Boost Price Target$63.41$75.00Buy
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
10/22/2025Boost Price Target$17.35$19.00Buy
Guardant Health, Inc. stock logo
GH
Guardant Health
9/25/2025Set Price Target$61.04$80.00
CareDx, Inc. stock logo
CDNA
CareDx
9/23/2025Reiterated Rating$14.99$22.00Buy
Guardant Health, Inc. stock logo
GH
Guardant Health
9/22/2025Reiterated Rating$59.15$70.00Buy
CareDx, Inc. stock logo
CDNA
CareDx
9/12/2025Reiterated Rating$13.53$22.00Buy
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
9/5/2025Boost Price Target$1.38$2.50Buy
Guardant Health, Inc. stock logo
GH
Guardant Health
9/4/2025Boost Price Target$59.08$70.00Buy
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
8/25/2025Boost Price Target$12.51$9.00Sell
Tempus AI, Inc. stock logo
TEM
Tempus AI
8/20/2025Boost Price Target$73.08$85.00Buy
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
8/12/2025Lower Price Target$41.52$60.00Buy
MaxCyte, Inc. stock logo
MXCT
MaxCyte
8/11/2025Reiterated Rating$1.38Neutral
Only one company survived this screen (Ad)

On May 21, 2026, a federal board voted unanimously to lend one gold company roughly $3 billion. The company passed a strict four box screen: American soil, full permits, meaningful scale, and small enough that the capital transforms it. Majors like Newmont failed on scale; juniors failed on permits. It trades at about 1/50th the size of Newmont, with final loan papers expected in the second half of 2026.tc pixel

See the company's name and ticker before the news spreads.
Tempus AI, Inc. stock logo
TEM
Tempus AI
8/8/2025Initiated Coverage$58.74$60.00Buy
Personalis, Inc. stock logo
PSNL
Personalis
8/6/2025Set Price Target$4.52$6.00
Tempus AI, Inc. stock logo
TEM
Tempus AI
4/21/2025Initiated Coverage$40.42$60.00Buy
MaxCyte, Inc. stock logo
MXCT
MaxCyte
3/12/2025Set Price Target$3.47$6.00Buy